MedTrace Logo

Pilot Study of the Effects of Resveratrol Supplement in Mild-to-moderate Alzheimer's Disease

NCT00743743 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2015-08-24

No results posted yet for this study

Summary

Objective: To determine the effects of resveratrol extract given in a 215 mg dose in a daily supplement currently available over the counter, on cognitive and global functioning in patients with mild to moderate AD on standard therapy.

Conditions

  • Alzheimer Disease

Interventions

DIETARY_SUPPLEMENT

Longevinex brand resveratrol supplement

1 capsule daily for 52 weeks containing 215 mg of resveratrol active ingredient

DIETARY_SUPPLEMENT

placebo

1 capsule of placebo daily for 52 weeks

Sponsors & Collaborators

  • Medical College of Wisconsin

    lead OTHER

Principal Investigators

  • Diana R Kerwin, MD · Medical College of Wisconsin

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2010-06-30
Completion
2010-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00743743 on ClinicalTrials.gov